OLEMA PHARMACEUTICALS

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

25 Nov 2024 17:30:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences

06 Nov 2024 07:01:11 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Nov 2024 16:44:36 By Nasdaq GlobeNewswire

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

09 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Oct 2024 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Sep 2024 16:49:15 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

21 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

06 Aug 2024 16:02:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jul 2024 16:29:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Jun 2024 16:28:00 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences in June

28 May 2024 07:03:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

15 May 2024 07:01:00 By Nasdaq GlobeNewswire

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

08 May 2024 16:02:00 By Nasdaq GlobeNewswire

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

08 May 2024 07:02:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 May 2024 16:37:00 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences in May

01 May 2024 07:02:00 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

08 Apr 2024 16:30:00 By Nasdaq GlobeNewswire